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Fibrosis is an important cause of morbidity and 
mortality in the lung and other organs. This can 
be seen in the interstitial lung diseases, includ-
ing idiopathic pulmonary fi  brosis (IPF), sclero-
derma, radiation-induced pulmonary fi  brosis, 
and bleomycin lung, where fi  broproliferative 
matrix molecule deposition, enhanced collagen 
accumulation, apoptosis, and alveolar septal 
rupture with honeycombing are often juxta-
posed and can lead to fatal consequences (1–4). 
Airway fi  brosis is also an important contributor 
to the pathogenesis of airway disorders, such as 
bronchiolitis obliterans syndrome and asthma 
(5–9). Surprisingly, the mechanisms of tissue 
fi  brosis in these important lung disorders are 
poorly understood.
The TGF-β family proteins are multifunc-
tional cytokines that play pivotal roles in diverse 
biologic processes, including the regulation of 
cell growth and survival, cell and tissue diff  er-
entiation, development, infl  ammation, immu-
nity, hematopoiesis, and tissue remodeling (10). 
TGF-β1 is essential for wound healing, stimu-
lates matrix molecule deposition, and has been 
implicated in the pathogenesis of a variety of 
fi  brotic disorders, including IPF, scleroderma, 
radiation-induced pulmonary fi  brosis, and asth  ma 
(10–17). The important roles that TGF-β1 
might play in IPF can be seen in human stud-
ies that demonstrated that bioactive TGF-β1 
is expressed in an exaggerated fashion in lungs 
from patients with IPF (14, 15, 18, 19). They can 
also be seen in animal studies that demonstrated 
that TGF-β1 is a critical mediator of bleomycin-
induced pulmonary fi  brosis (18, 20, 21) and 
that high dose adenoviral transfer of TGF-β1 
causes a progressive fi   brotic response in the 
lung in vivo and an IPF-like disease with fi  bro-
blastic foci in an explant culture system (19). 
Surprisingly, the mechanisms that TGF-β1 uses 
to mediate these tissue responses have not been 
fully defi  ned.
The semaphorins (SEMAs) are a large 
family of phylogenetically conserved, secreted, 
and membrane-bound proteins that are divided 
into eight classes based on sequence similari-
ties and distinct structural features (22, 23). 
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A variety of studies have documented the ability of members 
of this family to act as axon guidance molecules, and SEMA 
abnormalities have been implicated in the pathogenesis of 
neurologic disorders, such as Alzheimer’s disease and motor 
neuron degeneration (22, 23). SEMAs are also expressed on 
myeloid and lymphoid cells, including B cells, T cells, NK 
cells, and macrophages, and have been implicated in immune 
responses and the regulation of organogenesis, angiogenesis, 
apoptosis, and neoplasia (22–26). SEMA 7A, also called 
CDw108, was originally discovered based on sequence sim-
ilarities with the vaccinia virus SEMA homologue A39R 
and is now known to be the homologue of several viral 
SEMAs (25, 27–29). It is unique amongst SEMAs in that it 
is stabilized via a glycosylphosphatidylinositol membrane 
linkage (22–24, 29). In addition, unlike many SEMAs, which 
act as repulsive axonal guidance clues, SEMA 7A enhances 
central and peripheral axonal growth and is required for 
proper axon track formation during embryonic develop-
ment (22, 23). SEMA 7A may also play prominent roles in 
infl  ammation, immunity, and dental and osseous tissue re-
sponses based on its ability to stimulate macrophage chemo-
taxis and cytokine production and inhibit T cell function and 
its expression on odontoblasts, stimulation of osteoblast mi-
gration, and regulation of osteoclast fusion (24–26, 30). The 
eff  ects of SEMA 7A are believed to be mediated via at least 
two receptors, plexin C1 and the β1 integrin subunit (8, 23, 25). 
However, the mechanisms by which SEMA 7A mediates 
its tissue eff  ects are poorly understood. In particular, a rela-
tionship between SEMA 7A and TGF-β family proteins has 
not been defi  ned.
We hypothesized that SEMA 7A is regulated by TGF-β1 
and plays a critical role in TGF-β1–induced tissue fi  brotic and 
remodeling responses. To test this hypothesis, we character-
ized the eff  ects of transgenic TGF-β1 on the expression of 
SEMA 7A and its receptors in the murine lung. We also char-
acterized the eff  ector responses induced by transgenic TGF-β1 
in mice with WT and null SEMA 7A loci. These studies 
demonstrate that TGF-β1 is a potent stimulator of SEMA 7A 
and plexin C1 and the β1 integrin subunit. They also demon-
strate that SEMA 7A plays a key role in the pathogenesis of 
TGF-β1–induced fi  brosis and alveolar remodeling, and that 
TGF-β1 regulates the expression of SEMA 7A receptors, 
extra  cellular matrix (ECM) proteins, proteases, antiproteases, 
transcription factors, fi  brogenetic cytokines, apoptosis regula-
tors, and IL-13 receptors via Smad 2/3–independent, SEMA 
7A–dependent activation pathways.
RESULTS
TGF-𝗃1 regulation of the SEMA 7A system
To address the possibility that SEMA 7A contributes to TGF-
β1–induced responses in the murine lung, studies were fi  rst 
undertaken to determine if the expression of SEMA 7A or its 
putative receptors were regulated by transgenic TGF-β1. 
This was done by comparing the levels of SEMA 7A and 
plexin C1 and β1 integrins in the lungs from transgene (Tg) 
negative (−) and positive (+) mice at various times after Tg 
activation. These studies demonstrate that TGF-β1 is a potent 
stimulator of SEMA 7A and plexin C1 and β1 integrin 
mRNA accumulation in the lungs from doxycycline (Dox)-
treated Tg mice (Fig. 1, A–C). In situ hybridization also 
highlighted the presence of SEMA 7A mRNA in a variety of 
cells, including macrophages, epithelial cells, and cells in fi  -
brotic foci (Fig. 1 D and not depicted). The induction of 
SEMA 7A and its receptors was seen after as little as 2 d of 
Dox administration and persisted throughout the 28-d study 
interval (Fig. 1 and not depicted). It was associated with 
comparable levels of induction of SEMA 7A and β1 integrin 
protein accumulation in lung lysates but not in bronchoalve-
olar lavage (BAL) fl  uids (Fig. 1 E and not depicted). Interest-
ingly, the induction of plexin C1 and β1 integrins was SEMA 
7A dependent because TGF-β1 did not induce either SEMA 
7A receptor in SEMA 7A null mice (Fig. 1, B and C). This 
induction of SEMA 7A was also largely independent of 
Smad 3 signaling because similar levels of SEMA 7A induc-
tion were seen in TGF-β1 Tg+ mice with WT and null Smad 
3 loci (Fig. 1 F). These studies demonstrate that TGF-β1 is 
a potent stimulator of SEMA 7A and its receptors in the 
  murine lung. They also demonstrate that SEMA 7A is induced 
Figure 1.  Regulation of the SEMA 7A and its receptors by TGF-𝗃1. 
Tg− and Tg+ mice with WT+/+ and null−/− SEMA 7A loci and (+/+) and 
(−/−) Smad 3 loci were generated and evaluated after 2 wk of Tg activa-
tion. The levels of mRNA encoding SEMA 7A (A), plexin-C1 (B), and β1 
integrins (C) were evaluated using real-time RT-PCR. In situ hybridization 
with sense (S) and antisense (AS) probes was used to localize SEMA 7A 
mRNA (D). The arrow highlights a positively stained macrophage after 
2 wk of Tg activation. Western evaluations of lung lysates were used to 
evaluate the level of SEMA 7A and β1 integrin proteins (E and F). The 
values in A–C represent the mean ± SEM of evaluations in a minimum 
of fi  ve mice. *, P < 0.05. D–F are representative of a minimum of four 
similar evaluations.JEM VOL. 204, May 14, 2007  1085
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by TGF-β1 via a largely Smad 3–independent mechanism 
and plays a critical role in the induction of its own receptors 
in this setting.
Role of SEMA 7A in TGF-𝗃1–induced fi  brosis
To determine if the fi  brotic eff  ects of TGF-β1 were altered 
in the absence of SEMA 7A, we used biochemical (Sircol) 
and histologic approaches to quantitate the collagen in the 
lungs from Tg mice with WT and null SEMA 7A loci. In 
  accord with previous studies from our laboratory (31), trans-
genic TGF-β1 caused parenchymal and alveolar fi  brosis as well 
as a signifi  cant increase in lung collagen content in mice that 
expressed SEMA 7A normally (P < 0.001; Fig. 2, A and B). 
  Interestingly, the airway and parenchymal fi  brotic responses 
were diminished in the absence of SEMA 7A. After 14 d 
of Dox water administration, TGF-β1–induced collagen 
  accumulation was decreased by 80.1 ± 8.5% (P < 0.001) in 
SEMA 7A null versus WT animals (Fig. 2 B). These studies 
demonstrate that SEMA 7A plays an important role in the 
pathogenesis of TGF-β1–induced pulmonary fi  brosis in the 
murine lung.
Role of SEMA 7A in alveolar remodeling
In addition to inducing tissue fi  brosis, TGF-β1 induces alveo-
lar remodeling with septal destruction and an increase in al-
veolar chord length (31). To defi  ne the role(s) of SEMA 7A 
in these responses, we compared the alveoli from Tg mice 
with WT and null SEMA 7A loci. In accord with our prior 
report (31), an increase in lung destruction was readily appar-
ent in Tg mice that produced SEMA 7A normally (Fig. 2, 
C and D). Interestingly, null mutations of SEMA 7A caused 
a signifi  cant decrease in alveolar remodeling that was apparent 
in histologic and morphometric evaluations (Fig. 2, C and D). 
Overall, a null mutation of SEMA 7A caused a 72.3 ± 8.6% 
decrease in the TGF-β1–induced increase in alveolar chord 
length in mice on Dox water for 2 wk (P < 0.05). Thus, 
SEMA 7A plays an important role in the pathogenesis of 
TGF-β1–induced alveolar remodeling in the murine lung.
Role of SEMA 7A in TGF-𝗃1–induced DNA injury 
and cell death
Previous studies from our laboratory demonstrated that TGF-β1 
induces epithelial apoptosis and that this apoptotic response 
is a critical precursor of TGF-β1–induced fi  brosis (31). Thus, 
studies were undertaken to test the hypothesis that SEMA 
7A plays an important role in TGF-β1–induced apoptosis. 
This was done using TdT-mediated dUTP nick-end label-
ing (TUNEL) stains to compare the TGF-β1–induced DNA 
injury and cell death in transgenic mice with WT and null 
SEMA 7A loci. Transgenic TGF-β1 caused an impressive 
  increase in TUNEL staining in mice with WT SEMA 7A 
loci (Fig. 3, A and B). These TUNEL+ cells were largely 
epithelial cells as indicated by their histologic location and 
morphology (not depicted). This response was readily appre-
ciated after 2 d of Dox administration and decreased with 
longer periods of Tg activation (Fig. 3, A and B, and not de-
picted). At these time points, SEMA 7A appeared to play an 
important role in this response because the TUNEL staining 
Figure 2.  Roles of SEMA 7A in TGF-𝗃1–induced fi  brosis and 
  alveolar remodeling. Tg− and Tg+ mice with WT+/+ and null−/− SEMA 7A 
loci were generated and evaluated after 2 wk of Tg activation. The ability 
of TGF-β1 to induce tissue fi  brosis was assessed with trichrome histology 
evaluations (A) and Sircol collagen assays (B). The ability of TGF-β1 to 
induce alveolar remodeling was assessed with hematoxylin and eosin 
histology evaluations (C) and morphometric chord length assessments 
(D). The panels in A and C are representative of at least fi  ve similar experi-
ments. The values in B and D represent the mean ± SEM of evaluations 
in a minimum of fi  ve mice. *, P < 0.05; **, P < 0.001.
Figure 3.  Roles of SEMA 7A in TGF-𝗃1–induced DNA injury and 
cell death. Tg− and Tg+ mice with WT+/+ and null−/− SEMA 7A loci were 
generated and evaluated after 48 h of Tg activation. The ability of trans-
genic TGF-β1 to induce DNA injury and cell death was assessed with 
TUNEL evaluations (A and B). In A, the solid and open arrows highlight 
representative TUNEL staining alveolar epithelial and alveolar type II cells, 
respectively. Caspase-mediated ICAD cleavage is illustrated in C. A and C 
are representative of at least fi  ve similar experiments. The values in B 
represent the mean ± SEM of evaluations in a minimum of fi  ve mice. 
*, P < 0.05; **, P < 0.001.1086  SEMAPHORIN 7A AND TGF-β1 | Kang et al.
was decreased in lungs from Tg+ mice with null mutations of 
SEMA 7A (Fig. 3, A and B). This was readily appreciated 
  after 48 h of Dox administration, where TGF-β1–induced 
TUNEL staining was decreased by 43.3 ± 3.5% compared 
with Tg mice with WT SEMA 7A loci (P < 0.05; Fig. 3 B). 
This inhibition was associated with a signifi  cant decrease in 
caspase-mediated inhibitor of caspase-activated DNase (ICAD) 
cleavage (Fig. 3 C). Thus, these studies demonstrate that SEMA 
7A is an important contributor to TGF-β1–  induced DNA injury 
and cell death in the murine lung.
Roles of SEMA 7A in TGF-𝗃1–induced infl  ammation
To determine if SEMA 7A contributed to TGF-β1–induced 
tissue infl  ammation, we compared the cellularity of BAL fl  u-
ids and tissues from Tg+ mice with WT and null SEMA 7A 
loci. Similar numbers and types of cells were recovered in 
BAL fl   uids and tissues from Tg− mice regardless of their 
SEMA 7A genotype (not depicted). In accord with prior 
studies from our laboratory (31), transgenic TGF-β1 aug-
mented BAL and tissue cellularity by increasing macrophage 
and, to a lesser extent, lymphocyte and eosinophil accumula-
tion (not depicted). Importantly, the absence of SEMA 7A 
did not alter the magnitude or diff  erential of these responses 
(not depicted). Thus, these studies demonstrate that SEMA 
7A is not a major regulator of TGF-β1–induced infl  amma-
tion in the murine lung.
SEMA 7A regulation of transgenic TGF-𝗃1 and Smads
The decreased ability of TGF-β1 to induce tissue responses in 
the absence of SEMA 7A could be due to a decrease in the pro-
duction of transgenic TGF-β1 or a decrease in its ability to acti-
vate its eff  ector pathways. To diff  erentiate amongst these options, 
we compared the levels of total and active TGF-β1 in the lungs 
from Tg− and Tg+ mice with WT and null SEMA 7A loci. 
Figure 4.  Roles of SEMA 7A in the regulation of TGF-𝗃1 and 
Smads. Tg− and Tg+ mice with WT+/+ and null−/− SEMA 7A loci were 
generated and evaluated after 2 wk of Tg activation. The levels of total 
(■) and activated (□) TGF-β1 in BAL fl  uids from these mice were evalu-
ated by ELISA (A), and the levels of total and phosphorylated Smads 2 and 3 
were evaluated by Western analysis and evaluated with densitometry 
(B). Real-time RT-PCR was also used to quantitate the levels of mRNA 
encoding Smad 7 (C). The values in A and C represent the mean ± SEM of 
evaluations in a minimum of fi  ve mice. B is representative of four similar 
evaluations. N.S., not signifi  cant; *, P < 0.01.
Figure 5.  SEMA 7A, PI3K, PKB/AKT, and myofi  broblast accumula-
tion. Tg− and Tg+ mice with WT and null SEMA 7A loci were generated 
and evaluated after 2 wk of Tg activation. The levels of phosphorylation of 
PI3K and PKB/AKT were evaluated using Western blots with antibodies 
against the two forms of pAKT and PI3K (A). Myofi  broblast accumulation 
was assessed using IHC (B) and Western evaluations (C) with antibodies 
against α-smooth muscle actin (solid arrows) and myosin (open arrows). 
Sircol assays were used to evaluate the effects of PKB/AKT inhibition (Akt-
In) on collagen accumulation after 10 d of Dox incubation (D). A–C are 
representative of fi  ve similar evaluations. The values in D represent the 
mean ± SEM of evaluations in a minimum of fi  ve mice. *, P < 0.01.JEM VOL. 204, May 14, 2007  1087
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As can be seen in Fig. 4 A, these eff  ects appeared to be due, in 
great extent, to an alteration(s) in TGF-β1 eff  ector pathway 
activation because the levels of total and bioactive TGF-β1 in 
BAL from Tg+ mice with null SEMA 7A loci were compara-
ble or greater than those in fl  uids from Tg+ mice that make 
SEMA 7A normally.
To address the mechanism by which SEMA 7A contrib-
uted to TGF-β1 eff  ector responses, we started by determin-
ing if a defi  ciency of SEMA 7A altered the ability of TGF-β1 
to induce or activate Smads. These were done by comparing 
the Smads in Tg+ mice with WT and null SEMA 7A loci. 
Because Smads 2 and 3 mediate and Smad 7 inhibits TGF-β 
eff  ector pathway activation (10, 20), all three were evaluated. 
The levels and phosphorylation status of Smads 2 and 3 were 
similar in the lungs from Tg− mice with WT and null SEMA 
7A loci (Fig. 4 B). In accord with reports in the literature 
(10), Smad 2/3 phosphorylation was increased in TGF-β1 
Tg+ mice on Dox water (Fig. 4 B). Interestingly, the levels of 
phosphorylation of Smads 2 and 3 were similar in mice with 
WT and null SEMA 7A loci (Fig. 4 B). Transgenic TGF-β1 
also increased the levels of mRNA encoding of Smad 7 in 
mice with WT SEMA 7A loci (Fig. 4 C). This induction, 
however, was signifi  cantly decreased in Tg+ mice with null 
SEMA 7A loci (Fig. 4 C). When viewed in combination, 
these studies demonstrate that the defect in TGF-β1 eff  ector 
activation noted in SEMA 7A null mice was not associated 
with a decrease in Smad 2/3 phosphorylation or an increase 
in the expression of Smad 7.
SEMA 7A, phosphatidylinositol 3-kinase (PI3K), protein 
kinase B (PKB)/AKT, and myofi  broblasts
An evolving body of data has implicated a pathway that in-
volves integrin activation of PI3K and its downstream target 
PKB/AKT in the pathogenesis of myofi  broblast hyperplasia 
and tissue fi  brosis (32–35). To gain additional insight into 
the contributions of SEMA 7A, we compared the activation 
of PI3K and PKB/AKT and the accumulation of myofi  bro-
blasts in Tg+ mice with WT and null SEMA 7A loci. These 
studies demonstrated that TGF-β1 is a potent stimulator of 
PI3K phosphorylation, PKB/AKT phosphorylation at amino 
acids 473 and 308, and α-smooth muscle actin containing 
Figure 6.  Roles of SEMA 7A in the regulation of apoptosis regula-
tors. Tg− and Tg+ mice with WT+/+ and null−/− SEMA 7A loci were gen-
erated and evaluated after 2 d of Tg activation. Real-time RT-PCR was 
used to quantitate the levels of mRNA encoding Egr-1 (A), TNF-α (B), Bax 
(C), cathepsin S (D), and cathepsin B (E). The values represent the mean ± 
SEM of evaluations in a minimum of fi  ve mice. *, P < 0.05; **, P < 0.01.
Figure 7.  Roles of SEMA 7A in the regulation of ECM proteins 
and antiprotease. Tg− and Tg+ mice with WT+/+ and null−/− SEMA 7A 
loci were generated and evaluated after 2 wk of Tg activation. Real-time 
RT-PCR was used to quantitate the levels of mRNA encoding α1(I) col-
lagen (A), α2(I) collagen (B), type III collagen (C), fi  bronectin (FN) (D), 
elastin (E), laminin (F), and TIMP-1 (G). The values represent the mean ± 
SEM of evaluations in a minimum of fi  ve mice. *, P < 0.05; **, P < 0.01.1088  SEMAPHORIN 7A AND TGF-β1 | Kang et al.
myofi  broblast accumulation (Fig. 5). In all cases, these events 
were SEMA 7A dependent, with PI3K and PKB/AKT acti-
vation and myofi  broblast accumulation being signifi  cantly 
decreased in SEMA 7A–defi  cient mice (Fig. 5, A–C). α-smooth 
muscle myosin containing myocytes were not similarly al-
tered (Fig. 5 B). Importantly, TGF-β1–induced tissue fi  brosis 
was also signifi  cantly decreased in mice treated with the 
PKB/AKT inhibitor (Fig. 5 D) (34, 36). These studies high-
light a TGF-β1–activated, SEMA 7A–dependent pathway 
that involves PI3K and AKT and regulates myofi  broblast 
hyperplasia and   tissue fi  brosis.
SEMA 7A and TGF-𝗃1–induced apoptosis
Previous studies from our laboratory demonstrated that TGF-β1 
induces lung epithelial cell apoptosis via an early growth 
response protein (Egr)-1–dependent mechanism that involves 
multiple cell death pathways (31). Thus, to address the mech-
anisms by which SEMA 7A might contribute to TGF-β1–
  induced apoptosis, the ability of TGF-β1 to regulate Egr-1, the 
mitochondrial cell death pathway activator Bax, and death 
receptor cell death pathway activator TNF were evaluated. 
TGF-β1 was a potent stimulator of the levels of mRNA en-
coding all three moieties (Fig. 6, A–C). Cathepsins S and B, 
which have also been implicated in lung epithelial cell apop-
tosis (37), were similarly stimulated (Fig. 6, D and E). These 
responses were mediated, at least in part, by SEMA 7A be-
cause null mutations of SEMA 7A decreased the ability of 
TGF-β1 to stimulate Egr-1, Bax, TNF, and the cathepsins 
(Fig. 6). When viewed in combination, these studies demon-
strate that SEMA 7A plays an important role in TGF-β1 stim-
ulation of Egr-1 and the activation of the death receptor, 
mitochondrial, and cathepsin-mediated cell death pathways.
SEMA 7A and the mechanisms of pulmonary fi  brosis 
and alveolar remodeling
Studies were next undertaken to compare the regulation of 
collagens and selected proteases and antiproteases in the lungs 
from TGF-β1 Tg mice with WT and null SEMA 7A loci. 
These studies demonstrated that TGF-β1 is a potent stimula-
tor of the accumulation of mRNA encoding α1(I), α2(I), and 
type III collagens, fi  bronectin, elastin, and laminin (Fig. 7, 
A–F). Transgenic TGF-β1 also stimulated the expression of 
mRNA encoding tissue inhibitor of metalloproteinase 
(TIMP)-1 (Fig. 7 G). In all cases, SEMA 7A played an essen-
tial role in these inductive events because the ability of TGF-β1 
to regulate the accumulation of mRNA encoding these 
moieties was signifi  cantly decreased in mice with null muta-
tions of SEMA 7A (Fig. 7).
Studies were also undertaken to determine if the ability of 
TGF-β1 to regulate other known fi  broregulatory cytokines 
and their receptors was altered in the absence of SEMA 7A. 
Transgenic TGF-β1 caused signifi  cant increases in the levels of 
mRNA encoding fi  broblast growth factor (FGF)-2 (Fig. 8 A); 
the CCN growth factor family proteins CCN1 (Cyr-61), 
CCN2 (connective tissue growth factor; CTGF), CCN3 
(NOV), CCN4 (WISP-1), and CCN5 (WISP-2) (Fig. 8, B–F); 
and the IL-4 and IL-13 receptor components IL-4Rα and 
IL-13Rα2 (Fig. 8, G and H). In accord with our fi  ndings with 
the ECM proteins, these stimulatory eff  ects were also SEMA 
7A–dependent because they were all ameliorated in Tg+ mice 
with null SEMA 7A loci (Fig. 8, A–H). In contrast, IL-18, 
which inhibits tissue fi  brosis (38), was inhibited by SEMA 7A 
in Tg− and Tg+ mice (Fig. 8 I). In all cases, comparable altera-
tions in protein accumulation were noted (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20061273/DC1). 
These studies demonstrate that SEMA 7A plays a critical role 
in the ability of TGF-β1 to augment the accumulation of 
mRNA encoding collagens and other ECM proteins, anti-
proteases, fi   brostimulatory cytokines, and IL-13 receptors 
while inhibiting the expression of IL-18.
Figure 8.  Roles of SEMA 7A in the regulation of fi  broregulatory 
cytokines and IL-13 receptor components. Tg− and Tg+ mice with 
WT+/+ and null−/− SEMA 7A loci were generated and evaluated after 
2 wk of Tg activation. Real-time RT-PCR was used to quantitate the levels 
of mRNA encoding FGF-2 (A), CCN1 (B), CCN2 (C), CCN3 (D), CCN4 (E), 
CCN5 (F), IL-4Rα (G), IL-13Rα2 (H), and IL-18 (I). The values represent 
the mean ± SEM of evaluations in a minimum of fi  ve mice. *, P < 0.01; 
*, P < 0.001. JEM VOL. 204, May 14, 2007  1089
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SEMA 7A in bleomycin-induced pulmonary fi  brosis
Studies were also undertaken to determine if the biology of 
SEMA 7A that was defi  ned using our Tg modeling system 
was also relevant to fi  brotic responses that were induced by 
other stimuli. Bleomycin was chosen because TGF-β1 is 
known to play an important role in the pathogenesis of the 
fi  brosis it induces (18, 20, 21). As seen in Fig. 9, bleomycin 
caused a signifi  cant increase in pulmonary fi  brosis and colla-
gen accumulation that was most impressive 3 wk after intra-
tracheal administration. The response was associated with 
signifi  cant levels of infl  ammation, epithelial apoptosis, ICAD 
cleavage (Fig. 9 C and not depicted), and PKB/AKT phos-
phorylation (Fig. 9 C). In keeping with the results noted in 
our TGF-β1 Tg mice, bleomycin-induced epithelial apopto-
sis, ICAD cleavage, PKB/AKT activation, and tissue fi  brosis 
were signifi  cantly diminished and infl  ammation was not 
  altered in SEMA 7A null animals (Fig. 9, A–C, and not 
  depicted). At the 3-wk time point, SEMA 7A defi  ciency 
decreased the bleomycin-induced increase in pulmonary col-
lagen accumulation by 90.3 ± 7% (P < 0.001). Thus, SEMA 
7A plays an important role in the pathogenesis of the apopto-
sis, signaling, and fi  brotic responses induced by bleomycin as 
well as transgenic TGF-β1.
DISCUSSION
To gain insight into the pathogenesis of wound healing, tis-
sue fi  brosis, and tissue remodeling, the cellular and molecular 
events that TGF-β1 uses to induce these responses need to 
be understood. In these studies, we tested the hypothesis 
that SEMA 7A is induced by and plays a critical role in the 
pathogenesis of TGF-β1–induced fi  brotic and remodeling 
responses in the lung. These studies highlight previously un-
recognized relationships between SEMA 7A and TGF-β1. 
Specifi  cally, they demonstrate that SEMA 7A and its recep-
tors, plexin C1 and β1 integrins, are stimulated by TGF-β1. 
They also demonstrate that SEMA 7A plays a critical role in 
TGF-β1–induced fibrosis, myofibroblast hyperplasia, al-
veolar remodeling, and apoptosis, but does not contribute to 
TGF-β1–induced infl  ammation. Insights were also obtained 
from studies that demonstrate that TGF-β1 stimulates SEMA 
7A via a Smad 3–independent mechanism and enhances the 
expression of ECM proteins, CCN proteins, FGF-2, IL-13 
receptors, proteases, antiproteases, transcription factors, and 
apoptosis using a Smad 2/3–independent and SEMA 7A–
  dependent mechanism(s). TGF-β1 also activated PI3K and 
PKB/AKT via a SEMA 7A–dependent mechanism, and 
PKB/AKT inhibition decreased TGF-β1–induced fi  brosis. 
When viewed in combination, these observations demon-
strate that SEMA 7A participates in a Smad 2/3–independent 
pathway that involves PI3K and PKB/AKT and plays a cen-
tral role in the regulation of the fi  brogenic and remodeling 
eff  ector responses induced by TGF-β1. Because the fi  bro-
genic eff  ects of bleomycin were also ameliorated in SEMA 
7A null mice, they also demonstrate that the eff  ects of SEMA 
7A are not specifi  c for transgenic TGF-β1, thereby highlight-
ing the importance of our fi  ndings to other fi  brotic stimuli.
SEMAs play a central role in axonal guidance, and emerg-
ing evidence points to diverse functions of a variety of SEMAs 
(including SEMA 7A) in the immune system. These observa-
tions led to the present contention that the nervous and 
  immune systems share SEMA-containing regulatory pathways 
(22–24). Our studies demonstrate, for the fi  rst time, that 
SEMA 7A is a critical regulator of TGF-β1– and bleomycin-
induced tissue fi  brosis and remodeling. This contention, that 
SEMA 7A is an important regulator of tissue remodeling, is 
in accord with genetic studies highlighting the association of 
SEMA 7A polymorphisms and abnormal bone mineral den-
sity and vertebral fractures in Korean women (39), as well as 
studies highlighting the expression of SEMA on osteoblasts 
and the ability of SEMA 7A to regulate osteoblast migration 
and osteoclast fusion (25). Thus, these studies demonstrate 
that SEMA 7A–containing pathways, although contributing 
to neural and immune homeostasis, also contribute to the 
regulation of tissue fi  brosis and remodeling.
Figure 9.  Role of SEMA 7A in bleomycin-induced fi  brosis. Mice with 
WT+/+ and null−/− SEMA 7A loci were generated, given intratracheal bleo-
mycin or its vehicle control, and evaluated at intervals thereafter. At the 
3-wk time point, fi  brosis was assessed with tissue trichrome stains (A) and 
Sircol collagen assays (B). ICAD cleavage and PKB/AKT phosphorylation 
were evaluated 1 wk after bleomycin administration (C). A and C are repre-
sentative of fi  ve similar experiments. The values in B represent the mean ± 
SEM of evaluations in a minimum of fi  ve mice. *, P < 0.01; **, P < 0.001.1090  SEMAPHORIN 7A AND TGF-β1 | Kang et al.
The TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3) 
are synthesized as latent precursors that are complexed with 
latent TGF-β–binding proteins. They are activated by a vari-
ety of mechanisms that includes proteolytic cleavage and 
  integrin binding (10, 40). Once activated, they bind to 
heterodimeric receptors containing type I and type II recep-
tor components, both of which contain tyrosine kinase activ-
ity (10). The presentation of TGF-β1 to the type II receptor 
may also be assisted by accessory proteins, including β glycan 
and endoglin (10). In most cases, TGF-β1 signals via Smads, 
with Smads 2 and 3 being phosphorylated by TGF-βR1 
  kinase, binding to Smad 4, and translocating to the nucleus 
(10). Smad 7, on the other hand, inhibits Smad 2/3 phos-
phorylation and Smad 2/3/4 heterocomplex nuclear trans-
location (10, 20). Our studies demonstrate that mice lacking 
SEMA 7A have a striking defect in their ability to generate 
TGF-β1–induced lung fi   brosis and alveolar remodeling. 
They also demonstrate that this defi  ciency is associated with 
and potentially mediated by the inability of TGF-β1 to maxi-
mally stimulate collagen and other ECM proteins, fi  brostim-
ulatory CCN and other cytokines, antiproteases, transcription 
factors, and receptor components in the absence of SEMA 
7A. Previous studies using in vitro culture systems demon-
strated that Smad 3 is required for TGF-β1 stimulation of 
CCN2 or type II collagen (41, 42). In contrast, our studies 
demonstrate that SEMA 7A contributes to the tissue eff  ects of 
TGF-β1 in a Smad 2/3–independent fashion. On superfi  cial 
analysis, these observations would appear to confl  ict with one 
another. However, there is increasing evidence for Smad 2/3–
independent pathways that mediate the eff  ects of TGF-β1. 
One of the most intriguing pathways involves the activa-
tion of PI3K and subsequent activation of PKB/AKT (43). 
This pathway has been strongly associated with the regu-
lation of cell survival and is felt to play a key role in the 
diff  erentiation and survival of myofi  broblasts at the site of 
pulmonary fi  brosis (34). The PI3K pathway is also known to 
regulate other fi  brosis-relevant remodeling responses, includ-
ing cell proliferation, angiogenesis, and cell diff  erentiation 
(44). Our studies demonstrate that TGF-β1 induces myofi  -
broblast hyperplasia and activates PI3K and PKB/AKT via a 
SEMA 7A–dependent mechanism(s). They also demonstrate 
that PKB/AKT inhibition diminishes TGF-β1–induced fi  -
brosis. β1 integrins are known to participate in PI3K activa-
tion (34). This allows for the exciting hypothesis that SEMA 
7A–β1 integrin binding leads to PI3K activation and subse-
quent PKB/AKT phosphorylation, myofi  broblast accumula-
tion, and matrix molecule production. Additional investigation, 
however, will be required to more fully understand the nature 
and importance of this pathway.
Our studies demonstrate that the ability of TGF-β1 to 
stimulate tissue fi  brosis is markedly diminished in SEMA 7A 
null mice. They also highlight several events that can con-
tribute to this response. It is easy to understand how the 
  decreased levels of mRNA encoding ECM proteins and 
TIMP-1 that are seen in the absence of SEMA 7A could 
contribute to the inability of TGF-β1 to induce fi  brosis in 
SEMA 7A null animals. Our studies also demonstrate that 
TGF-β1 stimulates CCN1-5, FGF-2, and Egr-1 via SEMA 
7A–dependent mechanisms. These are important observa-
tions because CCN2 (also called CTGF) and related moieties 
CCN1 (Cyr-61), CCN3 (NOV3), CCN4 (WISP-1), and 
CCN5 (WISP-2) are induced during healing and at sites of 
fi  brosis where they play an essential role in the deposition of 
ECM proteins and are proposed to mediate the tissue eff  ects 
of TGF-β1 (45, 46). FGF-2 is also induced by TGF-β1 and 
has been shown to interact with TGF-β1 in the generation of 
tissue scarring (47–49). Similarly, Egr-1 is a zinc fi  nger tran-
scription factor that stimulates the production of platelet-
  derived growth factor, and FGF-2 and plays a critical role in 
TGF-β1–induced epithelial apoptosis (31, 50–52) (see below). 
Lastly, our studies demonstrate that SEMA 7A contributes 
to the inhibition of IL-18 production. These are   interesting 
fi  ndings in light of the recent observation that IL-18 inhibits 
tissue fi  brosis (38). When viewed in combination, these 
  observations suggest that SEMA 7A is a central mediator of a 
variety of pathways involved in TGF-β1 stimulation of tissue 
fi  brosis, including the stimulation of ECM proteins, stimula-
tion of antiproteases, expression of CCNs and FGF-2, induc-
tion of Egr-1, and inhibition of IL-18.
The “type 2 cytokine hypothesis of fi  brosis” suggests that 
tissue scarring occurs in chronic infl  ammatory disorders when 
cytokine balance is shifted in a type 2 direction (53, 54). In 
keeping with this hypothesis, IL-13 is expressed in an exag-
gerated fashion in a variety of fi  brotic diseases, including IPF, 
scleroderma, and asthma (5, 55–57). Studies from our labora-
tory and others have also demonstrated that IL-13 mediates 
its fi  brogenic eff  ects, in part, via its ability to induce and acti-
vate TGF-β1 (58, 59). IL-13 signals via a multimeric receptor 
complex involving IL-13RαI and IL-4Rα. IL-13 also binds 
to IL-13Rα2, which has, until recently, been believed to be 
a decoy receptor (60, 61). However, it has recently been pro-
posed to participate in the induction of TGF-β1 and the gen-
eration of tissue fi  brosis in bleomycin-induced lung injury 
(58). Our studies demonstrate, for the fi  rst time, that the ex-
pression of IL-13Rα2 and IL-4Rα is decreased in the lungs 
from TGF-β1 Tg mice that lack SEMA 7A. These observa-
tions highlight another mechanism by which SEMA 7A can 
contribute to the regulation of tissue fi  brotic responses. This 
mechanism might be particularly relevant to diseases such 
as asthma, scleroderma, and cirrhosis of the liver, in which 
IL-13 and TGF-β1 are believed to play important roles.
Alveolar remodeling is a fi  nal common pathway that con-
tributes to the pathogenesis of a variety of pulmonary diseases 
and disorders, including the honeycombing that is seen in 
advanced interstitial lung diseases and the alveolar destruction 
that is seen in pulmonary emphysema. As noted above, TGF-β1 
has been implicated in the pathogenesis of IPF and other 
interstitial lung diseases. Interestingly, TGF-β1 has also been 
implicated in the pathogenesis of cigarette-induced emphysema 
and the emphysema in patients with Marphan’s Syndrome 
(62–65). Previous studies from our laboratory demonstrated 
that TGF-β1 induces airway remodeling via a mechanism JEM VOL. 204, May 14, 2007  1091
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that involves epithelial apoptosis (31). These studies also 
demonstrated that Egr-1 plays a central role in this apoptosis 
response and that interventions that block this epithelial cell 
death response diminish TGF-β1–induced collagen accumu-
lation (31). The present studies add to our knowledge of this 
pathway by demonstrating that TGF-β1 induces Egr-1 via a 
SEMA 7A–dependent mechanism. They also demonstrate 
that TGF-β1 uses a similar SEMA 7A–dependent pathway(s) 
to stimulate TIMP-1 and cathepsins. When viewed in com-
bination, these observations suggest that SEMA 7A is a 
central regulator of TGF-β1–induced alveolar remodeling 
and that this regulation occurs at the level of epithelial apop-
tosis and local protease balance. They also suggest that the 
ability of SEMA 7A–based alterations to ameliorate TGF-β1–
induced fi  brosis can be attributed, at least in part, to the 
eff  ects of these interventions on the TGF-β1–induced epithelial 
apoptosis response.
In summary, these studies demonstrate that TGF-β1 is a 
potent stimulator of SEMA 7A and its putative receptors. 
They also highlight the critical roles that SEMA 7A and 
downstream PI3K and PKB/AKT play in TGF-β1 induction 
of tissue fi  brosis, remodeling, myofi  broblast hyperplasia, and 
apoptosis, as well as the important roles that SEMA 7A–
  dependent pathways play in TGF-β1 stimulation of SEMA 7A 
receptors, ECM proteins, proteases, antiproteases, transcrip-
tion factors, fi  brogenic and fi  broregulatory cytokines, and 
key cytokine receptors in the murine lung. Lastly, they dem-
onstrate that SEMA 7A mediates similar responses in bleo-
mycin-induced fi   brosis, thereby highlighting the potential 
importance of this pathway in other settings. TGF-β1–induced 
tissue fi  brosis and remodeling contribute to the pathogenesis 
of a wide variety of pulmonary and extra-pulmonary diseases 
and disorders. These fi  ndings suggest that interventions that 
regulate SEMA 7A, its receptors, or its signaling pathways 
may be therapeutically useful in disorders characterized by 
TGF-β1–mediated fi  brosis and remodeling. Additional inves-
tigations of the roles of SEMA 7A and the SEMA 7A path-
way in the pathogenesis of fi  brotic and remodeling disorders 
and the utility of SEMA 7A–based therapeutics in their treat-
ment are warranted.
MATERIALS AND METHODS
Overexpression Tg and null mutant mice. CC10-tTS-rtTA-TGF-β1 
Tg mice were generated in our laboratory, bred onto a C57BL/6 back-
ground for >10 generations, and used in these studies. These mice use the 
Clara cell 10-kD protein (CC10) promoter to specifi  cally target bioactive 
TGF-β1 to the lung. The methods that were used to generate and character-
ize these mice were described previously (31).
Mice with null mutations of SEMA 7A that had been bred onto a 
C57BL/6 background for >10 generations were provided by A.L. Kolodkin 
(Johns Hopkins University, Baltimore, MD) (22, 23). Mice with null muta-
tions of Smad 3 were obtained from the late A.B. Roberts (National Cancer 
Institute, Bethesda, MD). Before use, these mice were bred onto a C57BL/6 
background. These mice were bred with the TGF-β1 mice to obtain Tg 
mice with WT and null SEMA 7A or Smad 3 loci. Genotyping of TGF-β1 
Tg, SEMA 7A null, and Smad 3 null mice was accomplished according to 
the protocols established in our laboratory, the Kolodkin’s laboratory, and 
the literature (22, 23, 31, 66). All animal experiments were approved by the 
Yale School of Medicine Institutional Animal Care and Use Committee in 
accordance with federal guidelines.
Dox water administration. 6-wk-old Tg+ mice and Tg− littermate con-
trols were randomized to normal water or water containing 0.5 mg/ml Dox 
as described previously (31). Phenotypic alterations were evaluated at inter-
vals thereafter.
Quantifi  cation of lung collagen. Animals were anesthetized, a median 
sternotomy was performed, and right heart perfusion was accomplished with 
calcium and magnesium-free PBS. The heart and lungs were then removed 
en bloc. The right lung was frozen in liquid nitrogen and stored at −80°C 
until used. Collagen content was determined by quantifying total soluble 
collagen using the Sircol Collagen Assay kit (Biocolor) according to the 
manufacturer’s instructions. The data is expressed as the collagen content of 
the entire right lung.
Histologic analysis. The lungs were removed en bloc as described above, 
infl  ated at 25 cm pressure with PBS containing 0.5% low melting point aga-
rose gel, fi  xed, embedded in paraffi   n, sectioned, and stained. Hematoxylin 
and eosin, and Mallory’s trichrome stains were performed in the Research 
Histology Laboratory of the Department of Pathology at the Yale University 
School of Medicine.
Morphometric analysis. Alveolar remodeling was estimated from the mean 
chord length of the airspace as described previously by our laboratory (31, 67).
BAL and lung infl  ammation. Lung infl  ammation was assessed by BAL as 
described previously (31). The BAL samples from each animal were pooled 
and centrifuged. The number and type of cells in the cell pellet were deter-
mined with light microscopy.
TUNEL evaluations. End labeling of exposed 3′-OH ends of DNA frag-
ments was undertaken with the TUNEL in situ cell death detection kit AP 
(Roche Diagnostics) as described by the manufacturer. After staining, 
20 fi  elds of alveoli were randomly chosen for examination. The labeled cells 
were expressed as a percentage of total nuclei.
mRNA analysis. mRNA levels were assessed using real-time RT-PCR as-
says as described by our laboratories (31, 68). In these assays, total cellular RNA 
from the lungs were obtained using TRIzol reagent (Invitrogen) according 
to the manufacturer’s instructions. The primer sequences that were used that 
have not been previously reported by our laboratory can be found in Table S1, 
available at http://www.jem.org/cgi/content/full/jem.20061273/DC1.
Quantifi  cation of TGF-𝗃1. The levels of BAL TGF-β1 were determined 
by ELISA (R&D Systems) as per the manufacturer’s instructions. These 
evaluations were performed before and after acid activation to assess the 
levels of activated and total TGF-β1, respectively.
Immunoblot analysis. Lung lysates were prepared and Western analysis was 
undertaken with antibodies that reacted selectively with ICAD (Chemicon In-
ternational); SEMA 7A (AF1835; R&D Systems); Smads 2/3, phosphorylated 
Smad 2/3, Egr-1, PI3K, AKT, and phosphorylated AKT (Ser 473 and Thr 
308; all from Cell Signaling Technology); and β1 integrins (N-20), cathepsin 
S (C-19), CCN2 (CTGF, L-20), FGF-2 (H-131), and β-actin (H-196; all 
from Santa Cruz Biotechnology, Inc.) as described previously (31, 67).
In situ hybridization. In situ hybridization was undertaken as described 
previously by our laboratory (59). The mouse SEMA 7A probe (DNA frag-
ment corresponding to the sequence of mouse EST AA260340) was placed in 
a pBluescript II KS phagemid (Stratagene) between T7 and T3 promoter sites, 
and sense and antisense RNA probes were generated, labeled, and used.
Imunohistochemistry (IHC). IHC was undertaken to localize α-smooth 
muscle actin (DakoCytomation), and α-smooth muscle myosin heavy chain 1092  SEMAPHORIN 7A AND TGF-β1 | Kang et al.
(Biomedical Technology). These assays were undertaken as described previously 
by our laboratories (31, 67).
Akt inhibition. To defi  ne the role of PKB/AKT in TGF-β1–induced 
  fi  brosis, Akt inhibitor VII (15 μg/mouse; TAT-Akt-In; EMD Bioscience) 
(34, 36) and its vehicle control were used. They were given daily during the 
10-d study interval via an i.p. route starting 1 d before Dox activation.
Bleomycin administration. Bleomycin (0.075 U/mouse) or vehicle 
control was administered to C57BL/6 female mice as described by Jiang 
et al. (69).
Statistics. Normally distributed data are expressed as means ± SEM and as-
sessed for signifi  cance by Student’s t test or ANOVA as appropriate. Data 
that were not normally distributed were assessed for signifi  cance using the 
Wilcoxon rank sum test.
Online supplemental material. Fig. S1 is a representative Western blot 
illustrating accumulation of Egr-1, cathepsin S (Cat-S), CTGF, and FGF-2 
in lysates from Tg− and Tg+ mice with WT and null SEMA 7A loci. 
Table S1 lists the primer sequences used in the real-time RT-PCR re-
actions. The online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20061273/DC1.
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